Diagnosis and treatment of Parkinson´s disease (guideline of the German Society for Neurology)

• Published in: Neurological research and practice 2024-06, Vol.6 (1), p.30-12, Article 30
• Main Authors: Höglinger, Günter, Trenkwalder, Claudia
• Format: Article
• Language: English
• Subjects: Autonomic nervous system; Care; Deep brain stimulation; Diagnosis; Driving ability; Drug therapy; Guidelines; Medical diagnosis; Movement disorders; Neurodegenerative diseases; Neuroimaging; Neurology; Parkinson's disease; Patients; Treatment
• ISSN: 2524-3489; 2524-3489
• DOI: 10.1186/s42466-024-00325-4

The aim of this German national guideline is to optimize the clinical care of patients with Parkinson's disease (PD) in terms of diagnostics, drug and surgical treatment and care. This guidance was prepared for the German Society of Neurology (DGN) in collaboration with the Austrian Society of Neurology (ÖGN) and the Swiss Neurological Society (SNG) for German-speaking countries. The guidelines for the diagnosis and treatment of PD have been revised by a national expert group and the guideline commission of the DGN at S2k level. The main objective of these guidelines is to optimize the clinical care of PD patients regarding diagnosis, including early detection, technical diagnostic examinations, and pharmacological as well as invasive treatment options. The updated PD diagnosis and treatment guidelines are emphasizing optimized clinical care. Key revisions include preferring the name "Parkinson's disease" over previous terms and adopting International Parkinson and Movement Disorder Society (MDS) diagnostic criteria. Recommendations cover genetic and imaging diagnostics, initial pharmacotherapy considering efficacy and patient factors, and tailored pharmacological combinations for complications. Guidelines extend to managing cognitive, affective, psychotic, and autonomic symptoms, along with non-oral therapies like pump therapy and deep brain stimulation. Special situations like akinetic crisis, driving ability, and care concepts are addressed, ensuring comprehensive management for PD patients at various stages and conditions. This guidance reflects the state of the art at the beginning of 2024.